INTROduCTION
Coronary artery disease (CAD) is the most common entity among the whole spectrum of cardiovascular diseases, being the major cause of ambulatory visits, hospitalizations, and deaths in the European countries. 1 Stable angina pectoris is the initial clinical manifestation of CAD in almost half of the patients, 2 with an average 5% annual rate of subsequent development of fatal and nonfatal myocardial infarction, imposing a substantial economic burden on healthcare systems in Europe (data from the Euro Heart Survey).
3 Surprisingly, although today the development of medicine cannot ignore the economic background, evidence on the real costs of the management of CAD in Poland is lacking. Information about the real costs attributable to the management of CAD to be covered by the public payer in particular European countries (also in Poland) seems to be desirable. However, it is difficult to
ORIGINAL ARTICLE
Costs of management of patients with coronary artery disease in Poland: the multicenter RECENT study study. The questionnaire consisted of 9 sections regarding the particular categories of costs which had occurred within the last 12 months (see below for details).
The following cost distribution was applied prospectively for the purpose of this study. Total costs consisted of direct medical costs (paid by the public payer, i.e., those covered by the National Health Fund in Poland [Narodowy Fundusz Zdrowia -NFZ], public health insurance, and those paid by patients themselves), and indirect costs related to the absence from work and disability (covered by social insurance). Total direct medical costs were a sum of costs related to the following issues: drugs, medical consultations (in outpatient clinics), laboratory tests, diagnostic procedures (other than laboratory ones), invasive treatment, hospitalizations, emergency care. Indirect costs were a sum of sick leaves, pensions, and sickness benefits as a consequence of absence from work and/or disability due to CAD. Since the data regarding resource utilization are less sensitive to changing with time than the cost data, they were presented in the APPENDIX (available online).
Prevalence of coronary artery disease and related
costs Total costs, direct medical costs, and indirect costs were expressed as the annual costs per patient with CAD per year. All cost categories were estimated for the whole studied population, as well as separately for patients receiving GP vs. specialist care.
All the cost values were presented in Euro (€) in accordance with the average exchange rate of the Polish National Bank in 2005 (€1 = 4.0254 PLN).
The unit costs were obtained from the participating medical centers and published data based on the rates from the NFZ.
10,11 The cost of reimbursed drugs was taken from the list of reimbursed drugs in Poland.
12 For non-reimbursed drugs, pharmacy market prices were considered. The capital cost method was implemented for the calculations of the indirect cost related to absence from work (sick leaves). The indirect costs related to disability (pensions and/or sickness benefits) were calculated according to the average Polish Social Insurance Institution rates.
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Resource utilization was expressed as the annual number of particular resource use per 100 patients, with a distinction between patients under GP or specialist outpatient care.
The cost distribution was analyzed in the whole group and in prespecified subgroups, i.e., in patients receiving GP vs. specialist care, in men vs. women, in patients aged below 65 years vs. 65 years and over, and in patients with different severity of angina (subsequent Canadian Cardiovascular Society [CCS] classes).
A prevalence-based method was originally assigned to estimate the economic burden of CAD. The prevalence of CAD was estimated based on the data provided by the GUS in Healthcare Statistics for 2004. 6 The lower boundary estimate estimate these costs reliably. The incidence and prevalence of CAD as well as hospitalization rates and mortality vary considerably between different European countries. 3 There is a clear East-West gradient with the highest mortality rates in Eastern Europe. 4 There are also differences regarding the diagnostic and therapeutic procedures performed in patients with CAD across the European countries, 3 for example, between Poland and the United Kingdom. 5 Based on the estimates from the Central Statistical Office in Poland (Główny Urząd Statystyczny -GUS), the diagnosis of CAD in 2004 was confirmed in 2.9% to 8.6% of adult Poles. 6 According to the lower boundary estimates, it corresponded to 912,400 people with CAD with confirmed previous myocardial infarction. If this group would include also those without documented myocardial infarction, the total number of Poles suffering from CAD might even reach 2,718,300.
6 However, to estimate disease burden, the real population of patients with CAD should be considered as the lowest boundary estimate. As reported by Bandosz et al, 7 the eligible population for this estimation amounted to 706,670 patients suffering from chronic angina in 2005 in Poland.
Costs attributable to the management of patients with CAD account for the major part of public health expenditure, but so far these costs have not been assessed in Poland. Due to the aforementioned differences in the prevalence and management of CAD across Europe, all cost calculations based on the extrapolations from other European countries would be biased. Therefore, we performed a pharmacoeconomic analysis to estimate cost distribution related to both diagnosis and treatment of patients with CAD in Poland in 2005. We also aimed to estimate the global economic burden of CAD on the public healthcare system in 2005 in Poland, based on the population of patients with CAD, 7 which seemed to be the most realistic approach.
PATIENTs ANd mEThOds study sample The cost analysis constituted part of the RECENT study (Representative Evaluation of the CAD Treatment in the Outpatient Care in Poland) that was performed in Poland in 2005 under the auspices of the Polish Cardiac Society.
8,9
The study population consisted of a representative sample of outpatients (n = 2593) with an established diagnosis of CAD in 2005 in Poland. The majority of patients (n = 1977) received general practitioner (GP) care and the remaining patients (n = 616) received specialist care.
Details regarding the procedure of a representative selection of the analyzed subjects and the criteria for the diagnosis of CAD have been published previously. 8, 9 Time horizon and cost distribution The annual time horizon of the cost analysis was applied.
Information about cost components was collected using a questionnaire for cost assessment that had been exclusively constructed for this from work based on the Polish Social Insurance Institution rates instead of the capital-cost method 12 d multiway simulation assuming conditions A and B in relation to direct medical costs E multiway simulation assuming conditions A, B, and C.
Data processing and statistical analyses were performed using the STATISTICA software version 6 PL.
REsuLTs Clinical characteristics of the study group We analyzed the data of 2593 patients with an established diagnosis of CAD (mean age, 65 ±10 years; men, 55%; body mass index [BMI] for men, 28.3 ±4.0 kg/m 2 ; BMI for women, 29.0 ±4.8 kg/m 2 ; CCS class I, II, III, IV, 38%, 48%, 13%, and 1% of the patients, respectively). In 50% of the subjects, CAD was diagnosed on the basis of past myocardial infarction. In the remaining patients, the diagnosis of CAD was established based on positive electrocardiography exercise test (39%), typical chest pain in patients over 60 years of age (36%), history of acute coronary syndrome (29%), performed PCI (22%), performed coronary artery bypass grafting (CABG, 14%), or significant lesions confirmed in coronary angiography (18%). The history of hypertension, diabetes, dyslipidemia, heart failure, arrhythmia, stroke, transient ischemic attack, peripheral artery disease, and chronic obstructive pulmonary disease was found in 78%, 24%, 58%, 34%, 32%, 5%, 6%, 10% and 9% of the patients, respectively. Seventy-nine percent of the patients were overweight and 31% had metabolic syndrome; 11% of the subjects were active smokers. Detailed characteristics of the examined patients have been published previously. The annual resource utilization per 100 patients treated of the prevalence rate of Polish inhabitants with the diagnosis of CAD was defined as the sum of records of CAD with previous myocardial infarction, whereas the higher boundary estimate was defined as the sum of records of CAD not followed by myocardial infarction. 6 However, due to the risk of overestimation of the total costs caused by the high estimates of the population without confirmed disease, the real population approach was ultimately applied as the lowest boundary estimate, based on the data reported by Bandosz et al. 7 statistical analyses Cost data were compared using the nonparametric Wilcoxon test. A two-sided P less than 0.05 was considered statistically significant. All analyses were performed by means of weights computed according to a sampling design which enabled a representative estimation of the whole population of patients treated for CAD for at least 12 months in Poland.
Because of uncertainty surrounding some of the data concerning costs of invasive procedures and indirect costs, one-and multiway sensitivity analyses were performed for the above missing variables. The baseline values included in sensitivity analyses were based on the lower boundary estimates. The following conditions were prospectively assumed in sensitivity analyses: A one-way simulation assuming a decrease in drug cost by 10%, according to the declarations of the NFZ in Poland after the changes introduced at the end of 2005 in the lists of reimbursed drugs b one-way simulation assuming an increase in the number of coronary angiographies by 10% and an increase in the number of percutaneous coronary interventions (PCI) by 13%, according to the report published by the Working Group on Interventional Cardiology of the Polish Cardiac Society for the previous year 14 C one-way simulation adopting a method for calculation of indirect costs related to the absence for CAD is presented in the Appendix (available online). Total annual costs reached €2254.17 per patient with CAD in 2005 in Poland. Total direct medical costs and indirect costs accounted for 48% and 52% of the total cost, respectively. The percentage distribution of all cost categories in all patients with CAD was as follows: drugs -12%, medical consultations -2%, laboratory tests -1%, diagnostic procedures -6% invasive treatment -12%, hospitalizations -14%, emergency care -1%, indirect costs related to the absence from work -16%, and indirect costs related to disability -36%. The percentage distribution only within direct medical costs is demonstrated in FIGuRE 1.
Indirect costs related to the absence from work and disability are covered by social insurance, whereas direct medical costs are paid from 2 major sources, i.e., the public payer (NFZ) and patients themselves. Therefore, we distinguished direct medical costs attributable to CAD covered by the public payer (NFZ) in TAbLE 2. In Poland, most of healthcare services, with the exception of the patients' copayment for drugs, are financed from public sources. There was a marked difference in the participation of the public payer in financing cost components (30% of the cost of drugs vs. 93%-100% of the remaining cost categories) (TAbLE 2) .
The annual cost of pharmacological treatment (drugs) reached €278.54 per patient with CAD in 2005 in Poland. Only 30% of the costs related to pharmacological therapy in CAD were paid from public sources. The remaining 70% of the costs were paid by patients (52% for partially reimbursed drugs and 18% for non-reimbursed drugs,
FIGuRE 2).
Cost distribution in patients under general practitioner vs. specialist care All annual costs of CAD per patient were higher by 14% (€312.08) in subjects receiving specialist care compared with those receiving GP care (P <0.05) (TAbLE 1, FIGuRE 3) . Indirect costs related to absence from work and disability did not differ between the 2 groups. Therefore, the difference in total costs was driven mainly Age There was a trend towards higher direct medical costs of CAD covered by the public payer in subjects aged below 65 years compared with those 65 years and older (TAbLE 4) . This trend was due to observed higher costs related to medical consultations, invasive treatment, and hospitalizations in patients under the age of 65 years (TAbLE 4) . severity of angina symptoms Direct medical costs attributable to the management of CAD in Poland covered by the public payer were higher in patients with angina symptoms in CCS class II by 7% and in CCS classes III-IV by 48%-76% compared with those in CCS class depending on the cost category (TAbLE 5). Higher direct medical costs in subjects in CCS classes II-IV were driven mainly by the greater costs of diagnostic procedures, hospitalizations, and emergency care, and additionally invasive treatment in subjects in CCS class III (TAbLE 5) .
Economic burden of coronary artery disease in Poland in 2005 The lower boundary estimate of the GUS was the prevalence rate of 2.9% corresponding to 912,400 adult Polish inhabitants suffering from CAD with previous myocardial infarction. The higher boundary estimate of the GUS was the prevalence rate of 8.6%, corresponding to 2,718,300 of adult Polish inhabitants with by higher direct medical costs (drugs, diagnostic procedures, invasive treatment, and hospitalizations) among patients receiving specialist care (TAbLE 1, FIGuRE 4) . the calculation of the indirect costs significantly changed the final costs, causing a moderate overestimation. Detailed results of sensitivity analyses for the real population approach were presented in FIGuRE 5 .
dIsCussION To the best of our knowledge, this is the first pharmacoeconomic analysis performed among patients with stable CAD in one of the Eastern European countries after the political and social transition in the 1990s. We estimated that total annual costs attributable to CAD reached €2254.17 per patient in Poland in 2005, with 48% accounting for direct medical costs. Importantly, 81% of total direct medical costs were covered by the public payer, but this included only 30% of pharmacological treatment costs. Direct medical costs paid from public sources were higher in men compared with women, in patients aged below 65 years compared with those aged 65 years and older, in subjects with more severe vs. less severe angina symptoms, and in patients receiving specialist vs. GP care. CAD exemplifies a prevalent clinical entity that requires a long-term pharmacological treatment, is associated with frequent hospitalizations and invasive diagnostic and therapeutic procedures. In the 1990s in the United Kingdom, the economic burden of CAD was the greatest among all chronic diseases, 15 and the direct medical cost related to angina pectoris paid by the British National Health Service (NHS) was £669 million, representing approximately 1.3% of the total healthcare expenditure. 16 We have estimated that the total costs attributable to CAD could range from €2056.7 to €6127. According to the lower boundary estimate of the GUS, the total cost attributable to CAD in Poland in 2005 could reach €2056.7 million, and according to the lowest boundary estimate -€1592.0. More than half of this value (52%) was due to the indirect cost, 70% of which resulted from patients' disability (TAbLE 6) . Direct medical costs covered by the public payer in 2005 in Poland were estimated at €797.4 million in the model with the lower prevalence rate of CAD and as €617.6 million in the real population model (81% of total direct medical costs). It corresponded to 8.8% and 6.8%, respectively, of the total NFZ expenditure on healthcare in Poland in 2005. Costs attributable to pharmacological treatment of CAD covered by the public payer in 2005 were estimated at €88.6 million (8% of total direct medical costs from the public payer perspective). It corresponded to approximately 5.1% of total NFZ expenditures on drug reimbursement in Poland in 2005.
According to the higher GUS boundary estimate, total cost attributable to CAD in Poland in 2005 might have reached even €6127.5 million in 2005 (TAbLE 6) .
The results of both one-and multiway sensitivity analyses demonstrated that the assumed changes in drug costs and the numbers of invasive procedures did not significantly affect the overall total costs attributable to CAD in Poland. In contrast, the assumed approach regarding 129,716, 66,466, and 15,000 vs. 77,333, 120,893, and 13,583 , respectively for coronary angiography, PCI, and CABG, indicating the differences in the contribution of invasive cardiac procedures in total costs, with a prominent 2-fold increase in the number of PCI performed in the years 2005-2011 in Poland.
Since resource utilization data are less sensitive to changes with time than cost data, the particular resource use has been presented in the appendix to the main body of the article in order to improve the prevalence was estimated based on the GUS data. Nevertheless, the more realistic estimation seems to be based on the real population of patients with CAD registered in 2005, which diminishes the risk of cost overestimation. Therefore, this approach was ultimately applied as the lowest boundary estimate, and in this case the total cost attributable to CAD in Poland was estimated at €1592 million, and the direct medical cost of the management of CAD covered by the NFZ constituted about 7% of all public expenditure on healthcare in Poland in 2005, which was a high rate compared with the other European countries.
It should be emphasized that in Poland around 50% of total costs attributable to CAD corresponded to direct medical costs, while the same amount of money had to be paid from the public system of social insurance. The similar proportion between direct and indirect costs (1:1) related to the management of patients with CAD has been confirmed in other European countries.
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In 1995 in Sweden, annual direct medical and nonmedical costs per patient with CAD were estimated at $5563 and $5309, respectively.
18 Also in Switzerland, direct medical costs were reported to constitute 47% of the total costs and indirect costs -53%. 17 When planning cost strategies for the optimal management of patients with CAD, it is worth noting that total costs were significantly higher (14.4%) in patients receiving specialist vs. GP care in Poland. Hospitalizations and invasive the usefulness of our results for future comparisons based on the contemporary data. Although one may consider our analyses as not up-to-date, it is worth noting that there have been no publications in the past 20 years reporting the costs of the management of patients with CAD in Poland. Moreover, taking into consideration that beyond economic issues, the prevalence of CAD is increasing and the risk factors accelerating the progression of CAD are poorly controlled, particularly in diabetic subjects, 20-22 the provided data most likely underestimate rather than overestimate the current costs of the management of CAD in Poland.
Conclusions Our paper provides objective evidence for the high economic burden of CAD for the modern healthcare system in Poland. There is a need for further comprehensive monitoring and analysis of the costs related to this disease in order to support the decision making regarding optimal public resource allocation and the best social and economic benefits.
Further studies aiming at the development and implementation of innovative, cost-effective management strategies that would reduce the need for hospitalization (and the need for invasive procedures) are warranted.
